Abstract: Compositions comprising an aqueous medium, lipids and nonionic surfactants and methods of their use in preventing skin damages, such as in subjects exposed to radiation, are provided.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: In one embodiment, the present invention provides a composition comprising a plurality of microcapsules, each comprising a shell and a core carrying an active agent selected from the group consisting of: (a) a non-hydrophilic active agent and (b) a hydrophilic active agent dissolved or suspended in an oil; wherein the shell comprises a polymeric coating, and wherein at least a portion of the microcapsules in a sample of the composition are spherical when the sample of the microcapsules is viewed in a scanning electron microscope with a magnification in the range of between ×2000 and ×50000.

Abstract: A device for diagnosing a wound in a patient, the device comprising: at least two electrodes configured to be placed on the skin of the patient, wherein the at least two electrodes are placed in the vicinity of the wound; and at least one signal processor operatively coupled with the at least two electrodes, wherein the at least one signal processor is configured to: i) detect and record an endogenous alternating electrical signal in an area of the wound, ii) transform said endogenous alternating electrical signal into a voltage versus frequency spectrum using a Fast Fourier Transform (FFT) algorithm, and iii) diagnose the wound as a chronic wound if the voltage for a frequency between 65-200 Hz of the frequency spectrum is below 10?7.3±10% volts and as an acute wound if the voltage for a frequency between 65-200 Hz of the frequency spectrum is above 10?7.3±10% volts.

Abstract: An electrical stimulator system that includes a component configured to deliver an electrical current to a wound, the electrical current being a stochastic alternating current (AC) signal characterized by a frequency spectrum within the range of 0.5-2000 Hz. The system optionally includes electrodes through which the electrical current is delivered. The electrodes are optionally configured to be affixed on two opposing sides of the wound.

Abstract: A device for diagnosing a wound in a patient, the device comprising: at least two electrodes configured to be placed on the skin of the patient, wherein the at least two electrodes are placed in the vicinity of the wound; and at least one signal processor operatively coupled with the at least two electrodes, wherein the at least one signal processor is configured to: i) detect and record an endogenous alternating electrical signal in an area of the wound, ii) transform said endogenous alternating electrical signal into a voltage versus frequency spectrum using a Fast Fourier Transform (FFT) algorithm, and iii) diagnose the wound as a chronic wound if the voltage for a frequency between 65-200 Hz of the frequency spectrum is below 10?7.3±10% volts and as an acute wound if the voltage for a frequency between 65-200 Hz of the frequency spectrum is above 10?7.3±10% volts.

Abstract: Described herein are electrical markers, specifically alternate current (AC) signals whose appearance in patients with wounds, specifically chronic wounds, correlates to the prognosis of the wounds. Related methods that can be used for diagnosis and treatment of wounds are disclosed. Also described herein are methods that can be used to identify electrical signals of wounds.

Abstract: A method for diagnosing non-visible (occult) maladies in a human patient, the method comprising: (a) deploying at least two electrodes spaced apart on the skin of the patient; (b) detecting and recording a bioelectrical signal in and around said electrodes, the bioelectrical signal being a stochastic signal; (c) transforming the stochastic signal into a voltage versus frequency spectra using a Fast Fourier Transform (FFT) algorithm; (d) comparing a graph of a resultant FFT level of the patient to at least one graph of a baseline FFT level; and (e) determining a presents of a non-visible (occult) malady based on said comparison. Methods for monitoring a treatment regimen for non-visible (occult) maladies and for modulating the amplitude of endogenous bioelectrical stochastic signals in a human patient are also disclosed.

Abstract: Described herein are electrical markers, specifically alternate current (AC) signals whose appearance in patients with wounds, specifically chronic wounds, correlates to the prognosis of the wounds. Related methods that can be used for diagnosis and treatment of wounds are disclosed. Also described herein are methods that can be used to identify electrical signals of wounds.

Abstract: The present invention provides a gastro-retentive delivery assembly (GRDA) comprising a folded multi-layered device comprising a macromolecule-containing compartment bordered by enveloping layers and one or more enforcing strips, the device being adapted to unfold when in a subject's stomach, whereupon unfolding, the macromolecule is released from said device via at least one aperture in an enveloping layer. The invention also provides a method for gastroretentive delivery of macromolecules via the GRDA of the invention; a method of preparing the GRDA of the invention as well as a method for treating a subject for a pathological condition, making use of the GRDA of the invention.

Abstract: The present invention provides a gastro-retentive diagnostic assembly (GRDA) for use in determining a condition of a subject's gastrointestinal tract (GI tract), comprising a folded single or multi-layered device comprising a diagnostic utility, such as a contrasting agent, the device prior to folding being essentially planar, and included in a delivery system for oral intake, the delivery system being adapted to release the device once in the stomach, whereupon release said device unfolds into an unfolded shape that results in the retention of the device in the stomach. Further provided are methods of determining a condition of a subject's GI tract by the use of the GRDA of the invention, as well as uses of a single or multi-layered device comprising a diagnostic utility when in a folded or unfolded shape, and method of preparing the GRDA of the invention.

Abstract: Methods of use of pharmaceutical compositions and novel peptides which are conformationally constrained backbone cyclized somatostatin analogs, having somatostatin receptor subtype selectivity, are disclosed. These patterns or receptor subtype selectivity provide compounds having improved therapeutic utility. Methods for synthesizing the somatostatin analogs and for screening of the somatostatin analogs are also disclosed. Furthermore, pharmaceutical compositions comprising somatostatin analogs are disclosed.